$WMT

Stocks making the biggest moves midday: Walmart, Deere, CrowdStrike, Moderna & more

Walmart (WMT) fell 9% as Q2 revenue beat estimates but same-store sales and EPS guidance missed. Deere (DE) rose 9% after Q3 earnings and revenue topped estimates, raising full-year guidance. Webull (WB) gained 4% with Q2 adjusted operating income and revenue beating expectations. Crypto-related stocks like Coinbase (COIN) and Mara Holdings (MARA) climbed 7-12% following Bitcoin and Ether's surge. Moderna (MRNA) plunged 25% after a 177% gain, as trial results for a skin cancer vaccine were met w

Original reporting
Published Aug 20, 2026, 6:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 6:25 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Stocks making the biggest moves midday: Walmart, Deere, CrowdStrike, Moderna & more — source image
Decision brief

The 30-second read

$WMTBearishMed
01

Why it matters

Multiple companies reported fresh earnings and guidance, driving significant intraday price swings.

02

Market read

The article provides first‑report earnings data for several large caps, creating actionable trading opportunities.

03

What to watch

Supply‑chain pressures on Walmart and Deere, regulatory scrutiny on crypto could affect longer‑term trends.

Relevance 7/10Novelty 7/10Timing: midday today

Background

Midday market roundup highlighting earnings releases and sector moves.

Company-level read

Ticker impact

$WMTBearishMedium confidence
Context

Walmart reported Q2 revenue beat but same-store sales and EPS guidance missed expectations, causing a 9% drop.

Expected impact

Potential continued downside toward support around $140.

Evidence & confidence

Guidance shortfall and sales miss suggest near-term weakness.

$DEBullishMedium confidence
Context

Deere posted Q3 EPS $5.10 vs $4.70 estimate and raised full-year net income guidance, sending shares up ~9%.

Expected impact

May test resistance near $150.

Evidence & confidence

Beat and guidance lift suggest further upside.

$COINBullishLow confidence
Context

Coinbase gained about 8% as crypto stocks rallied on Bitcoin and Ether price surge.

Expected impact

Potential move toward $80 resistance.

Evidence & confidence

Move driven by broader crypto sentiment, not company‑specific news.

$RIGBullishMedium confidence
Context

Transocean rose 2% after signing a $300 million two‑year contract with ONGC for an ultra‑deepwater drillship.

Expected impact

May test near $30 resistance.

Evidence & confidence

Contract size is material for the sector.

$MRNABearishMedium confidence
Context

Moderna plunged 25% after a prior 177% rally, despite late‑stage skin‑cancer vaccine trial meeting key goals.

Expected impact

Potential further decline toward $70 support.

Evidence & confidence

Market re‑prices after large prior rally.

$NDSNBullishMedium confidence
Context

Nordson raised full‑year adjusted earnings guidance to $11.80‑$12, beating consensus, sending shares up ~7%.

Expected impact

May test resistance near $140.

Evidence & confidence

Guidance lift is material for valuation.

$AAPBearishMedium confidence
Context

Advance Auto Parts fell 25% after mixed Q2 results, with revenue miss and same‑store sales decline.

Expected impact

Potential move toward $120 support.

Evidence & confidence

Weak top‑line and sales data suggest near‑term weakness.

$COTYBearishMedium confidence
Context

Coty dropped 9% after reporting a larger quarterly loss and labeling fiscal 2027 a "transition year."

Expected impact

May test support near $30.

Evidence & confidence

Guidance and loss miss are negative catalysts.

Market effects

Earnings beats and misses across industrials, consumer discretionary, and tech influence sector rotation.

U.S. equities show mixed reactions; crypto rally lifts related stocks.

Broad market move reflects earnings season and crypto sentiment globally.

Counterpoint

Some beaten‑down names like Walmart may rebound if guidance improves; crypto stocks could reverse if Bitcoin stalls.

Key entities

  • Walmart

    Retail giant with earnings miss.

  • Deere

    Agricultural equipment maker with earnings beat.

Related articles

$WMTHighAI 8/10

Walmart posts sluggish sales with slowest U.S. growth in years

Walmart Inc. reported quarterly sales below expectations, with U.S. same-store sales growth at 2.6%, the slowest in over six years. Shares fell 7.4% post-results. The company cited pricing pressure in its pharmacy business due to federal drug price negotiations. Despite challenges, Walmart raised its full-year guidance and expects tariff refunds to help lower prices.

$WMTHighAI 8/10

TSX Takes Bruises Early Afternoon

The TSX fell 104.72 points to 36,297.07 on Thursday, following global market declines. Walmart shares dropped 9% after missing sales forecasts and lowering earnings guidance. U.S. stocks also declined, with the Dow, S&P 500, and Nasdaq all down. Bond yields rose, and oil prices increased due to geopolitical tensions.

$COTYHighAI 8/10

Why Coty Stock Crashed Today

Coty (COTY) shares fell 10% after missing Q4 2026 earnings expectations, reporting a $0.02 loss per share on $1.3B sales. The company cited Middle East conflict for weak sales. CEO Markus Strobel highlighted sales and profit targets, but GAAP losses worsened to $0.16 per share. Coty aims to reduce debt and focus on core brands, expecting $300M in positive free cash flow in fiscal 2027.

$WMTHighAI 8/10

Walmart Stock Tumbles After Earnings -- Analysts Say 'Buy the Dip'

Walmart's (WMT) stock fell 7% after reporting U.S. sales growth of 2.6%, below expectations, and a weaker near-term profit outlook. Analysts from Jefferies, RBC, UBS, and Evercore ISI maintained positive ratings, citing growth in e-commerce, advertising, and membership. The decline pushed shares below their year-start level, reflecting investor concerns over margins and valuation.

$MRNAHighAI 9/10

Moderna's cancer vaccine trials could pave way for shift in care

Moderna's cancer vaccine, developed with Merck, showed positive results in a Phase 3 trial, extending survival and reducing cancer recurrence. The vaccine is personalized to each patient's cancer. Moderna is also testing the technology on other cancers, with trials ongoing. The company's stock price rose significantly following the trial results, according to TD Cowen analyst Tyler Van Buren.